PCM
GRCE

Prelude Capital Management’s Grace Therapeutics GRCE Stock Holding History

Prelude Capital Management’s Portfolio GRCE Stock Details GRCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-10,074
Closed -$46.6K – 1584
2026
Q1 		$46.6K Buy
+10,074
New +$39.6K ﹤0.01% 1130
2019
Q4 		– Sell
-11
Closed -$1K – 2318
2019
Q3 		$1K Buy
+11
New +$1.02K ﹤0.01% 1648

Other funds holding GRCE

Cerity Partners
Cerity Partners New York $82.7B AUM 28.53% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
MS
Maven Securities St Helier, Jersey $5.06B AUM 59.27% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return
CF
Cantor Fitzgerald New York $9.31B AUM 73.66% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Prelude Capital Management's GRCE Position: Q2 2026 in Review

Prelude Capital Management sold out of Grace Therapeutics (GRCE) in Q2 2026, closing a stake of 10,074 shares — an estimated $46.6K sold.

Prelude Capital Management first reported a position in GRCE in Q3 2019 and held it in 2 quarters. The position peaked at $46.6K in Q1 2026. 33 funds tracked by Wall St. Rank hold GRCE as of Q2 2026.

  • Prelude Capital Management reported no remaining Grace Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Prelude Capital Management sold 10,074 Grace Therapeutics shares in Q2 2026, an estimated $46.6K.
  • Prelude Capital Management first reported a position in Grace Therapeutics in Q3 2019 and held it in 2 quarters.
  • Prelude Capital Management's Grace Therapeutics position peaked at $46.6K in Q1 2026.
  • 33 funds tracked by Wall St. Rank held Grace Therapeutics as of Q2 2026.

Based on Prelude Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.